Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Equity

v3.21.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
VentureEast Settlement
Warrant Exchange
Common Stock
Common Stock
VentureEast Settlement
Common Stock
Warrant Exchange
Additional Paid-in Capital
Additional Paid-in Capital
VentureEast Settlement
Additional Paid-in Capital
Warrant Exchange
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning Balance (shares) at Dec. 31, 2018       924,000              
Beginning Balance at Dec. 31, 2018 $ 6,802     $ 0     $ 164,458     $ 60 $ (157,716)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Stock based compensation—employees 370           370        
Issuance of common stock (shares)       952,000              
Issuance of common stock $ 5,412           5,412        
Issuance of common stock, conversions and exchanges (shares) 174,000     225,000              
Issuance of common stock, conversions and exchanges $ 962           962        
Increase in fair value of embedded conversion option 547           547        
Fractional shares settlement (shares)       (2,000)              
Fractional shares settlement (5)           (5)        
Issuance of common stock to vendor (shares)       5,000              
Issuance of common stock to vendor 39           39        
Unrealized loss on foreign currency translation (34)                 (34)  
Net loss (6,708)                   (6,708)
Ending Balance (shares) at Dec. 31, 2019       2,104,000              
Ending Balance at Dec. 31, 2019 7,385     $ 0     171,783     26 (164,424)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Stock based compensation—employees 173           173        
Issuance of common stock (shares)       1,618,000 3,000            
Issuance of common stock 3,074 $ 12         3,074 $ 12      
Issuance of common stock, conversions and exchanges (shares)       399,000   11,000          
Issuance of common stock, conversions and exchanges 1,577   $ 10       1,577   $ 10    
Oncospire retirement (1)           (1)        
Increase in fair value of embedded conversion option 0                    
Unrealized loss on foreign currency translation (249)                 (249)  
Net loss (8,001)                   (8,001)
Ending Balance (shares) at Dec. 31, 2020       4,135,000              
Ending Balance at Dec. 31, 2020 $ 3,980     $ 0     $ 176,628     $ (223) $ (172,425)